ArticleMolecular biology reports2026
Atranorin suppresses the LUCAT1/STAT3 axis to induce ferroptotic cell death in ovarian cancer.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveOvarian cancer remains the most lethal gynecological malignancy and represents a major cause of cancer-related mortality among women worldwide. Despite advances in therapeutic strategies, treatment efficacy is frequently limited by systemic toxicity, chemoresistance, and disease recurrence, highlighting the urgent need for novel, mechanism-based targeted therapies with improved safety profiles. In the present study, we investigated the anti-cancer activity of atranorin (ATR), a naturally derived small-molecule compound, with a particular focus on its ability to induce ferroptosis by modulation of the LUCAT1/STAT3 signaling axis.
methodsHuman ovarian cancer cell lines (OVCAR-3 and SKOV-3) and normal ovarian surface epithelial (OSE) cells were employed to evaluate cytotoxic selectivity and mechanistic effects.
resultsATR selectively inhibited proliferation of ovarian cancer cells while exerting minimal cytotoxicity toward normal OSE cells. Mechanistic analyses demonstrated that ATR significantly suppressed LUCAT1 and STAT3 expression at both mRNA and protein levels, as confirmed by qRT-PCR and Western blotting. Concomitantly, ATR upregulated ferroptosis-related genes and proteins. Biochemical assessments revealed increased intracellular reactive oxygen species (ROS), elevated malondialdehyde (MDA) and iron accumulation, and depletion of glutathione (GSH), collectively indicating activation of ferroptotic cell death. Furthermore, ATR significantly impaired migratory and invasive capacities of ovarian cancer cells. Collectively, our findings identify ATR as a compound capable of inducing biochemical features consistent with ferroptosis in ovarian cancer through suppression of the LUCAT1/STAT3 axis. DISCUSSION: These results uncover a previously uncharacterized mechanistic pathway underlying ATR-mediated anti-tumor effect and support its potential development as a targeted therapeutic candidate for ovarian cancer management.
Indexed as
Identifiers
42496762What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.